Johnson Chair in Surgical and Medical Oncology at Vanderbilt University Medical Center in Nashville, Tennessee, said, “I think the SPOTLIGHT phase 3 trial has [had] the largest impact this year because it has identified a new molecular marker, claudin 18.2, and a new targeted antibody [zolbet...